SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.
ACE-2
COVID-19
RBD
alum
coronavirus
pseudovirus
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
pubmed:
14
4
2021
medline:
30
9
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (
Identifiants
pubmed: 33847226
doi: 10.1080/21645515.2021.1901545
pmc: PMC8054496
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2356-2366Subventions
Organisme : NIAID NIH HHS
ID : P30 AI161943
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI140872
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129893
pubmed: 33731300
Mol Ther. 2014 Dec;22(12):2142-2154
pubmed: 25156127
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Bio Protoc. 2016 Dec 5;6(23):
pubmed: 28018942
Nat Commun. 2021 Mar 1;12(1):1346
pubmed: 33649323
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
N Engl J Med. 2020 Oct 29;383(18):1701-1703
pubmed: 32846056
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
J Immunol. 2010 Dec 15;185(12):7583-95
pubmed: 21098232
Nat Biotechnol. 1997 Sep;15(9):871-5
pubmed: 9306402
Microbes Infect. 2020 May - Jun;22(4-5):165-167
pubmed: 32305501
PLoS Negl Trop Dis. 2020 Apr 10;14(4):e0008271
pubmed: 32275667
Nat Rev Immunol. 2020 Jul;20(7):399-400
pubmed: 32499636
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
PLoS Negl Trop Dis. 2020 Jul 29;14(7):e0008548
pubmed: 32726304
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Sci Transl Med. 2020 Nov 4;12(568):
pubmed: 33077678
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090
pubmed: 32897177
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Infect Immun. 2018 Mar 22;86(4):
pubmed: 29311242
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
J Virol. 1995 Nov;69(11):6705-11
pubmed: 7474080
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Sci Immunol. 2020 Nov 18;5(53):
pubmed: 33208380
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Vaccine. 2018 Mar 27;36(14):1853-1862
pubmed: 29496347
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
J Infect Dis. 2021 Feb 24;223(4):699-708
pubmed: 32851411
Curr Trop Med Rep. 2020 Mar 3;:1-4
pubmed: 32219057
Hum Vaccin Immunother. 2014;10(3):648-58
pubmed: 24355931
Vaccine. 2020 Nov 3;38(47):7533-7541
pubmed: 33039209
J Immunol Methods. 2017 Jan;440:74-82
pubmed: 27840065
Sci Rep. 2020 Nov 18;10(1):20085
pubmed: 33208827
Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81
pubmed: 15474494
PLoS One. 2015 Jul 14;10(7):e0132479
pubmed: 26172046
Appl Microbiol Biotechnol. 2021 May;105(10):4153-4165
pubmed: 33959781
Adv Drug Deliv Rev. 2021 Mar;170:71-82
pubmed: 33421475
N Engl J Med. 2020 Nov 12;383(20):1986-1988
pubmed: 32663910
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Pharm Sci. 2017 Aug;106(8):1961-1970
pubmed: 28456726